During the past decade, Siteman Cancer Center - Washington University Medical Campus conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 1 clinical trials were completed, i.e. on average, 20% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 1 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Siteman Cancer Center - Washington University Medical Campus" #1 sponsor was "Kura Oncology, Inc." with 1 trials, followed by "OncXerna Theraputics, Inc." with 1 trials sponsored, "Pancreatic Cancer Action Network" with 1 trials sponsored, "Takeda" with 1 trials sponsored and "Vaccinex Inc." with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Siteman Cancer Center - Washington University Medical Campus" #1 collaborator was "Merck Sharp & Dohme LLC" with 2 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Siteman Cancer Center - Washington University Medical Campus" are "Carcinoma, Non-Small-Cell Lung" (1 trials), "Gastric Cancer" (1 trials), "GastroEsophageal Cancer" (1 trials), "HNSCC" (1 trials) and "HRAS Gene Mutation" (1 trials). Many other conditions were trialed in "Siteman Cancer Center - Washington University Medical Campus" in a lesser frequency.

Most popular intervention types in "Siteman Cancer Center - Washington University Medical Campus" are "Drug" (5 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Bavituximab" (1 trials), "Dose - Pamrevlumab combined with gemcitabine and nab-paclitaxel" (1 trials), "Dose -mFOLFIRINOX" (1 trials), "Dose- Canakinumab and Spartalizumab combined with nab-paclitaxel and gemcitabine" (1 trials) and "Drug: Dose -SM-88" (1 trials). Other intervention names were less common.

The vast majority of trials in "Siteman Cancer Center - Washington University Medical Campus" are 5 trials for "All" genders.

Currently, there are NaN active trials in "Siteman Cancer Center - Washington University Medical Campus". undefined are not yet recruiting, 2 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Siteman Cancer Center - Washington University Medical Campus, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Siteman Cancer Center - Washington University Medical Campus, 2 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".